Skip to content
AgilVax Logo
  • Team
  • Products
    • xCT-ADC
    • xCT-mAb
    • AX09-VLP
  • Pipeline
  • Publications
  • Cancer
    • Target
    • Focus
  • News
  • Contact
Jordan2020-06-08T12:40:42+00:00Monday 8 Jun|

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

testing

Jordan2020-04-27T16:39:35+00:00Monday 27 Apr|

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines

testing

Jordan2019-06-11T17:03:44+00:00Tuesday 11 Jun|

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

testing

Jordan2019-04-26T18:56:56+00:00Friday 25 Jan|

Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.

testing

Jordan2019-04-26T18:51:00+00:00Tuesday 8 Jan|

xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain

testing

Jordan2019-04-26T18:46:34+00:00Thursday 6 Sep|

xCT (SLC7A11)-mediated metabolic reprogramming promotes non- small cell lung cancer progression

testing

Jordan2019-04-26T19:00:05+00:00Wednesday 6 Dec|

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo

testing

Jordan2019-04-25T19:38:54+00:00Friday 25 Aug|

The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.

testing

Jordan2019-04-29T20:03:49+00:00Wednesday 5 Apr|

Poster > AX09: An Immunotherapy Candidate Targeting Breast Cancer Stem Cell Protein xCT

testing

Jordan2019-04-29T15:12:42+00:00Monday 3 Oct|

Poster > Development of a VLP-based RSV vaccine targeting pre-fusion F-protein

testing

12Next
footer-logo
Contact Us

Team

xCT-ADC

xCT-mAb

AX09-VLP

Publications

Target

Focus

News

Contact

Copyright © AgilVax 2020. Website Design and Development by Ingenuity Software Labs